

TTKHC:SECL:GJ:015:20

January 28, 2020

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 001

National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra East Mumbai 400 051

SCRIP CODE: 507747

SCRIP CODE: TT

TTKHLTCARE

Dear Sirs,

Re: Unaudited Financial Results along with Limited Review Report for the Third Quarter and period ended 31st December, 2019 (Standalone)

We are forwarding herewith the Unaudited Financial Results along with the Limited Review Report from the Statutory Auditors of the Company, for the Third Quarter and period ended 31<sup>st</sup> December, 2019 (Standalone), duly reviewed by the Audit Committee at their meeting held earlier in the day and approved by the Board of Directors of the Company at their Meeting held today.

Kindly take the above documents on record.

Thanking you

Yours faithfully

For TTK Healthcare Limited

(S KALYANARAMAN)

Wholetime Director & Secretary

Chlinhaway

Encl.: a/a

CIN: L24231TN1958PLC003647



# TTK HEALTHCARE LIMITED

Regd. Office: No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

# STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED 31ST DECEMBER, 2019 (STANDALONE)

[Prepared in compliance with the Indian Accounting Standards (Ind AS)]

								(Rs. in lakhs)
۵.	Particulars		For	the Quarter e	nded		e figures for	For the Year
SI. No.							od ended	ended
			(31/12/2019)	,	(31/12/2018)		(31/12/2018)	
1	Rever	nue from Operations	16,580,71	Unaudited	Unaudited	Unaudited	Unaudited	Audited
II.		Income		16,485.46				62,788.36
III.	-	Income (I + II)	222.39					775.35
IV.	Exper		16,803.10	16,680.61	15,078.74	51,528.47	49,374.74	63,563.71
	-	Cost of materials consumed	0.505.05	0.704.40				
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Purchase of Stock-in-trade	2,595.95		2,693.99			
		Changes in inventories of Finished Goods, Work-in-progress	3,882.00	3,962.09	3,674.70	12,973.14	12,878.40	16,711.14
	а	and Stock-in-trade	(59.71)	(103.19)	(26.02)	(263.51)	(367.69)	(576.99)
		Employee benefits expense	3,684.96	3,769.58	3,100.81	11,209.26	9,816.94	13,070.09
	1.7	inance Costs	90.87	75.13	69.93	234.02	269.00	337.90
	(f) [	Depreciation and Amortization Expense	365.74	357.86	346.88	1,078.04	1,058.36	1,466.85
	.07	Other Expenses	5,607.29	5,223.92	4,416.16	16,635.31	14,751.55	18,503.86
		Expenses (IV)	16,167.10	16,076.81	14,276.45	49,680.11	46,180.32	59,637.76
V.	Profit	/ (Loss) before Exceptional Items and Tax (III - IV)	636.00	603.80	802.29	1,848.36	3,194.42	3,925.95
VI.	Excep	tional Items	-	-	-	-	-	
VII.	Profit	/ (Loss) before Tax (V - VI)	636.00	603.80	802.29	1,848.36	3,194.42	3,925.95
VIII.	Tax Expense:							
	(1) C	Current Tax	193.00	69.00	290.00	500.00	1,180.00	1,495.00
	1-7	Peferred Tax	(4.76)	156.73	24.02	158.60	72.51	(6.42)
IX.	Profit VIII)	/ (Loss) for the period from Continuing Operations (VII-	447.76	378.07	488.27	1,189.76	1,941.91	2,437.37
Χ.	Profit /	(Loss) from Discontinued Operations	_					
XI.		xpense of Discontinued Operations						
XII.		(Loss) from Discontinued Operations (after tax) (X -XI)			-	-	-	-
XIII.		/ (Loss) for the period (IX + XII)	447.76	378.07	488.27	4 490 76	4.044.04	0.407.07
XIV.		Comprehensive Income:	447.70	370.07	400.27	1,189.76	1,941.91	2,437.37
		) Items that will not be reclassified to profit or loss	(90.07)	(93.62)	166.81	(275.58)	194.99	234.17
	(ii	i) Income tax relating to items that will not be reclassified to profit or loss	3.99	(10.35)	-	(12.76)	-	25.75
	(B) (i)							
	(ii		-	-	-	-		-
XV.	[Comp	Comprehensive Income for the period (XIII + XIV) orising Profit / (Loss) and Other Comprehensive Income period]	361.68	274.10	655.08	901.42	2,136.90	2,697.29
	Paid-u	p Equity Share Capital (Face Value Rs.10 per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
	Other	Equity as per Balance Sheet of previous accounting year ding Revaluation Reserve)	-	.,	.,	.,,,,,,,,,,	., // 10.00	23,288.53

XVI.	Earnings per Equity Share (For Continuing Operations):						
	(1) Basic (in Rs.)	3.17	2.68	3.46	8.42	13.74	17.25
	(2) Diluted (in Rs.)	3.17	2.68	3.46	8.42	13.74	17.25
XVII.	Earnings per Equity Share (For Discontinued Operations):						
	(1) Basic (in Rs.)		-	-	-		-
	(2) Diluted (in Rs.)	-	-	-	-	- 1	
XVIII.	Earnings per Equity Share (For Continuing and Discontinued Operations):						
	(1) Basic (in Rs.)	3.17	2.68	3.46	8.42	13.74	17.25
	(2) Diluted (in Rs.)	3.17	2.68	3.46	8.42	13.74	17.25

#### NOTES:

- (1) The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on 28th January, 2020 at Chennai.
- (2) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (3) The Company has elected to exercise the option permitted under Section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised Provision for Income Tax for the Quarter and period ended 31st December, 2019 and remeasured Deferred Tax Assets at the lower tax rate prescribed in the said Section.
- (4) The Company has implemented Ind AS 116 "Leases" with effect from 1st April, 2019, using Modified Retrospective Method and electing to account for leases ending within 12 months as Short Term Leases. Effect of the same is not material.
- (5) The previous period's / year's figures have been regrouped and reclassfied, wherever necessary to conform to the current period's / year's presentation.
- (6) This Statement is also available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).

FOR TTK HEALTHCARE LIMITED

T T RAGHUNATHAN EXECUTIVE VICE CHAIRMAN

Place : Chennai

Date : January 28, 2020



## TTK HEALTHCARE LIMITED

Regd. Office: No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES FOR THE QUARTER AND PERIOD ENDED 31ST DECEMBER, 2019

SI.	Particulars		For	the Quarter e	nded	Year to date the perio	For the Year ended	
No.			(31/12/2019)	(30/09/2019)	(31/12/2018)	(31/12/2019)	(31/12/2018)	(31/03/2019)
			Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.		gment Revenue:						
	(Sa (a)	les and Other Operating Income)						
	(b)	Pharmaceuticals	6,183.63		5,272.28			21,645.89
	(c)	Consumer Products	4,539.37	4,339.52	4,140.43			
	(d)	Medical Devices	1,108.47	1,137.88	1,040.77	3,445.76		
		Protective Devices Foods	2,614.72	2,637.04	2,596.09	7,545.71	8,283.44	10,313.83
	(e) (f)	Others	2,129.40		1,842.32	6,496.20		7,470.06
	Tot		5.12	9.85	12.80		46.08	72.35
			16,580.71	16,485.46	14,904.69	50,925.23	48,827.57	62,788.36
	100010200	s : Inter Segment Revenue	10 500 51				-	
2.	Net Sales / Income from Operations Segment Results:		16,580.71	16,485.46	14,904.69	50,925.23	48,827.57	62,788.36
-	[Pro	ofit (+) / Loss (-) before tax and interest from each ment]						
	(a)	Pharmaceuticals	655.16	720.09	422.97	1,890.43	1,579.52	2,110.62
	(b)	Consumer Products	672.65	511.70	900.49	1,789.81	2,851.51	3,324.73
	(c)	Medical Devices	196.15	201.53	199.67	605.06	697.48	935.26
	(d)	Protective Devices	(311.19)	(260.39)	(119.21)	(734.87)	(289.39)	(262.84)
	(e)	Foods	(245.39)	(246.65)	(291.35)	(746.59)	(606.46)	(847.21)
	(f)	Others	4.60	6.70	8.88	27.05	25.20	44.13
	Tota	al	971.98	932.98	1,121.45	2,830.89	4,257.86	5,304.69
	Les	s : Finance Cost	90.87	75.13	69.93	234.02	269.00	337.90
	Les	s : Unallocable Expenses (Net of Unallocable Income)	245.11	254.05	249.23	748.51	794.44	1,040.84
	Tota	al Profit (+) / Loss (-) before tax	636.00	603.80	802.29	1,848.36	3,194.42	3,925.95
			As on 31/12/2019	As on 30/09/2019	As on 31/12/2018	As on 31/12/2019	As on 31/12/2018	As on 31/03/2019
3.	Seg	ment Assets						
	(a)	Di-						
		Pharmaceuticals	6,164.49	6,789.98	5,214.23	6,164.49	5,214.23	5,627.36
	(b)	Consumer Products	6,164.49 3,859.27	6,789.98 3,607.54	5,214.23 2,851.81	6,164.49 3,859.27	5,214.23 2,851.81	5,627.36 3,229.20
	(b)							Seas Managaran School
	-	Consumer Products	3,859.27	3,607.54	2,851.81	3,859.27	2,851.81	3,229.20
	(c)	Consumer Products Medical Devices	3,859.27 4,457.36	3,607.54 4,255.02	2,851.81 4,174.09	3,859.27 4,457.36	2,851.81 4,174.09	3,229.20 4,018.25
	(c) (d)	Consumer Products Medical Devices Protective Devices	3,859.27 4,457.36 8,214.19	3,607.54 4,255.02 8,429.43	2,851.81 4,174.09 8,571.20	3,859.27 4,457.36 8,214.19	2,851.81 4,174.09 8,571.20	3,229.20 4,018.25 8,009.33
	(c) (d) (e) (f) Tota	Consumer Products Medical Devices Protective Devices Foods Others	3,859.27 4,457.36 8,214.19 8,491.07	3,607.54 4,255.02 8,429.43 8,522.28	2,851.81 4,174.09 8,571.20 9,330.35	3,859.27 4,457.36 8,214.19 8,491.07	2,851.81 4,174.09 8,571.20 9,330.35	3,229.20 4,018.25 8,009.33 8,918.46
	(c) (d) (e) (f) Tota	Consumer Products Medical Devices Protective Devices Foods Others	3,859.27 4,457.36 8,214.19 8,491.07 145.98	3,607.54 4,255.02 8,429.43 8,522.28 140.75	2,851.81 4,174.09 8,571.20 9,330.35 107.31	3,859.27 4,457.36 8,214.19 8,491.07 145.98	2,851.81 4,174.09 8,571.20 9,330.35 107.31	3,229.20 4,018.25 8,009.33 8,918.46 122.11
	(c) (d) (e) (f) Tota Una	Consumer Products  Medical Devices  Protective Devices  Foods  Others  al	3,859.27 4,457.36 8,214.19 8,491.07 145.98 31,332.36	3,607.54 4,255.02 8,429.43 8,522.28 140.75 31,745.00	2,851.81 4,174.09 8,571.20 9,330.35 107.31 <b>30,248.99</b>	3,859.27 4,457.36 8,214.19 8,491.07 145.98 31,332.36	2,851.81 4,174.09 8,571.20 9,330.35 107.31 <b>30,248.99</b>	3,229.20 4,018.25 8,009.33 8,918.46 122.11 29,924.71
4.	(c) (d) (e) (f) Tota Una	Consumer Products  Medical Devices  Protective Devices  Foods  Others  al	3,859.27 4,457.36 8,214.19 8,491.07 145.98 31,332.36 16,213.71	3,607.54 4,255.02 8,429.43 8,522.28 140.75 31,745.00 15,520.33	2,851.81 4,174.09 8,571.20 9,330.35 107.31 30,248.99 14,472.42	3,859.27 4,457.36 8,214.19 8,491.07 145.98 31,332.36 16,213.71	2,851.81 4,174.09 8,571.20 9,330.35 107.31 30,248.99 14,472.42	3,229.20 4,018.25 8,009.33 8,918.46 122.11 29,924.71 14,250.03
4.	(c) (d) (e) (f) Tota Una	Consumer Products  Medical Devices  Protective Devices  Foods  Others  al	3,859.27 4,457.36 8,214.19 8,491.07 145.98 31,332.36 16,213.71	3,607.54 4,255.02 8,429.43 8,522.28 140.75 31,745.00 15,520.33	2,851.81 4,174.09 8,571.20 9,330.35 107.31 30,248.99 14,472.42	3,859.27 4,457.36 8,214.19 8,491.07 145.98 31,332.36 16,213.71	2,851.81 4,174.09 8,571.20 9,330.35 107.31 30,248.99 14,472.42	3,229.20 4,018.25 8,009.33 8,918.46 122.11 29,924.71 14,250.03
4.	(c) (d) (e) (f) Tota Una Tota Seg	Consumer Products  Medical Devices Protective Devices Foods Others al Illocated al Assets ment Liabilities	3,859.27 4,457.36 8,214.19 8,491.07 145.98 31,332.36 16,213.71 47,546.07	3,607.54 4,255.02 8,429.43 8,522.28 140.75 31,745.00 15,520.33 47,265.33	2,851.81 4,174.09 8,571.20 9,330.35 107.31 30,248.99 14,472.42 44,721.41	3,859.27 4,457.36 8,214.19 8,491.07 145.98 31,332.36 16,213.71 47,546.07	2,851.81 4,174.09 8,571.20 9,330.35 107.31 30,248.99 14,472.42 44,721.41	3,229.20 4,018.25 8,009.33 8,918.46 122.11 29,924.71 14,250.03 44,174.74
4.	(c) (d) (e) (f) Tota Una Tota Seg (a)	Consumer Products  Medical Devices Protective Devices Foods Others al Illocated al Assets ment Liabilities Pharmaceuticals	3,859.27 4,457.36 8,214.19 8,491.07 145.98 31,332.36 16,213.71 47,546.07	3,607.54 4,255.02 8,429.43 8,522.28 140.75 31,745.00 15,520.33 47,265.33	2,851.81 4,174.09 8,571.20 9,330.35 107.31 30,248.99 14,472.42 44,721.41	3,859.27 4,457.36 8,214.19 8,491.07 145.98 31,332.36 16,213.71 47,546.07	2,851.81 4,174.09 8,571.20 9,330.35 107.31 30,248.99 14,472.42 44,721.41	3,229.20 4,018.25 8,009.33 8,918.46 122.11 29,924.71 14,250.03 44,174.74 5,188.06 4,771.64
4.	(c) (d) (e) (f) Tota Una Tota Seg (a) (b)	Consumer Products  Medical Devices Protective Devices Foods Others al Illocated al Assets ment Liabilities Pharmaceuticals Consumer Products	3,859.27 4,457.36 8,214.19 8,491.07 145.98 31,332.36 16,213.71 47,546.07 6,162.13 4,362.55	3,607.54 4,255.02 8,429.43 8,522.28 140.75 31,745.00 15,520.33 47,265.33 6,196.95 4,518.49	2,851.81 4,174.09 8,571.20 9,330.35 107.31 <b>30,248.99</b> 14,472.42 <b>44,721.41</b> 4,662.16 4,369.94	3,859.27 4,457.36 8,214.19 8,491.07 145.98 31,332.36 16,213.71 47,546.07 6,162.13 4,362.55	2,851.81 4,174.09 8,571.20 9,330.35 107.31 <b>30,248.99</b> 14,472.42 <b>44,721.41</b> 4,662.16 4,369.94 1,018.23 2,200.21	3,229.20 4,018.25 8,009.33 8,918.46 122.11 29,924.71 14,250.03 44,174.74 5,188.06 4,771.64 865.09
4.	(c) (d) (e) (f) Tota Una Seg (a) (b) (c)	Consumer Products  Medical Devices Protective Devices Foods Others al Illocated al Assets ment Liabilities Pharmaceuticals Consumer Products Medical Devices	3,859.27 4,457.36 8,214.19 8,491.07 145.98 31,332.36 16,213.71 47,546.07 6,162.13 4,362.55 1,096.49	3,607.54 4,255.02 8,429.43 8,522.28 140.75 31,745.00 15,520.33 47,265.33 6,196.95 4,518.49 1,052.09	2,851.81 4,174.09 8,571.20 9,330.35 107.31 30,248.99 14,472.42 44,721.41 4,662.16 4,369.94 1,018.23	3,859.27 4,457.36 8,214.19 8,491.07 145.98 31,332.36 16,213.71 47,546.07 6,162.13 4,362.55 1,096.49	2,851.81 4,174.09 8,571.20 9,330.35 107.31 30,248.99 14,472.42 44,721.41 4,662.16 4,369.94 1,018.23 2,200.21 1,014.46	3,229.20 4,018.25 8,009.33 8,918.46 122.11 29,924.71 14,250.03 44,174.74 5,188.06 4,771.64 865.09
4.	(c) (d) (e) (f) Tota Una Tota Seg (a) (b) (c) (d)	Consumer Products  Medical Devices Protective Devices Foods Others al Illocated al Assets ment Liabilities Pharmaceuticals Consumer Products Medical Devices Protective Devices	3,859.27 4,457.36 8,214.19 8,491.07 145.98 31,332.36 16,213.71 47,546.07 6,162.13 4,362.55 1,096.49 2,290.93	3,607.54 4,255.02 8,429.43 8,522.28 140.75 31,745.00 15,520.33 47,265.33 6,196.95 4,518.49 1,052.09 2,386.02 1,513.19 134.16	2,851.81 4,174.09 8,571.20 9,330.35 107.31 30,248.99 14,472.42 44,721.41 4,662.16 4,369.94 1,018.23 2,200.21 1,014.46 138.65	3,859.27 4,457.36 8,214.19 8,491.07 145.98 31,332.36 16,213.71 47,546.07 6,162.13 4,362.55 1,096.49 2,290.93 1,416.25 134.74	2,851.81 4,174.09 8,571.20 9,330.35 107.31 30,248.99 14,472.42 44,721.41 4,662.16 4,369.94 1,018.23 2,200.21 1,014.46 138.65	3,229.20 4,018.25 8,009.33 8,918.46 122.11 29,924.71 14,250.03 44,174.74 5,188.06 4,771.64 865.09 1,413.48 903.64 138.01
4.	(c) (d) (e) (f) Tota Seg (a) (b) (c) (d) (e) (f) Tota Tota Seg (a) (b) (c) (d) (e) (f) Tota Seg (f) Tota Seg (f) (f) Tota Seg (f) (f) (f) Tota Seg (f)	Consumer Products  Medical Devices Protective Devices Foods Others al Illocated al Assets ment Liabilities Pharmaceuticals Consumer Products Medical Devices Protective Devices Foods Others	3,859.27 4,457.36 8,214.19 8,491.07 145.98 31,332.36 16,213.71 47,546.07 6,162.13 4,362.55 1,096.49 2,290.93 1,416.25	3,607.54 4,255.02 8,429.43 8,522.28 140.75 31,745.00 15,520.33 47,265.33 6,196.95 4,518.49 1,052.09 2,386.02 1,513.19	2,851.81 4,174.09 8,571.20 9,330.35 107.31 30,248.99 14,472.42 44,721.41 4,662.16 4,369.94 1,018.23 2,200.21 1,014.46	3,859.27 4,457.36 8,214.19 8,491.07 145.98 31,332.36 16,213.71 47,546.07 6,162.13 4,362.55 1,096.49 2,290.93 1,416.25	2,851.81 4,174.09 8,571.20 9,330.35 107.31 30,248.99 14,472.42 44,721.41 4,662.16 4,369.94 1,018.23 2,200.21 1,014.46	3,229.20 4,018.25 8,009.33 8,918.46 122.11 29,924.71 14,250.03 44,174.74 5,188.06 4,771.64 865.09 1,413.48 903.64

### NOTES:

Place

Date

Chennai

January 28, 2020

- Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management.
- 2. Details of products included in each of the Segments are as below:
  - Pharmaceuticals include products for both Human and Veterinary use.
  - Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Freshners, etc.
  - Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
  - Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products.
  - Foods comprise manufacturing and marketing of Food Products.
  - "Others" include Printing and Publishing of Maps and Atlases.
- The segment-wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
- The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED

T T RAGHUNATHAN EXECUTIVE VICE CHAIRMAN



#### TTK HEALTHCARE LIMITED

Regd. Office: No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

#### EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED 31ST DECEMBER, 2019 (STANDALONE)

(Rs. in lakhs)

							(NS. III IAKIIS)	
SI.	Particulars	For the Quarter ended			Year to date figures for the period ended		For the Year ended	
No.		(31/12/2019)	(30/09/2019)	(31/12/2018)	(31/12/2019)	(31/12/2018)	(31/03/2019)	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1.	Total Income from Operations	16,580.71	16,485.46	14,904.69	50,925.23	48,827.57	62,788.36	
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)		603.80	802.29	1,848.36	3,194.42	3,925.95	
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items)		603.80	802.29	1,848.36	3,194.42	3,925.95	
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items)	447.76	378.07	488.27	1,189.76	1,941.91	2,437.37	
5.	Total comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]		274.10	655.08	901.42	2,136.90	2,697.29	
6.	Equity Share Capital (Face Value of Rs.10/- per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	
7.	Other Equity as per the Balance Sheet of previous accounting year (excluding Revaluation Reserve)				V		23,288.53	
8.	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)							
	(a) Basic (in Rs.)	3.17	2.68	3.46	8.42	13.74	17.25	
	(b) Diluted (in Rs.)	3.17	2.68	3.46	8.42	13.74	17.25	

#### NOTES:

- (1) The above is an extract of the detailed Statement of Unaudited Financial Results for the Third Quarter and period ended 31st December, 2019, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (2) The full financial results for the Third Quarter and period ended 31st December, 2019 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).
- (3) These financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on 28th January, 2020 at Chennai.
- (4) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (5) The Company has elected to exercise the option permitted under Section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised Provision for Income Tax for the Quarter and period ended 31st December, 2019 and remeasured Deferred Tax Assets at the lower tax rate prescribed in the said Section.
- (6) The Company has implemented Ind AS 116 "Leases" with effect from 1st April, 2019, using Modified Retrospective Method and electing to account for leases ending within 12 months as Short Term Leases. Effect of the same is not material.
- (7) The previous period's / year's figures have been regrouped and reclassfied, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED

Place

: Chennai

Date

: January 28, 2020

T T RAGHUNATHAN
EXECUTIVE VICE CHAIRMAN

#### PKF SRIDHAR & SANTHANAM LLP

Chartered Accountants

## Independent Auditor's Review Report on review of Interim financial results

#### To the Board of Directors of TTK Healthcare Limited

We have reviewed the accompanying Statement of Unaudited financial results ("the Statement") of TTK Healthcare Limited ("the Company") for the quarter and period ended 31<sup>st</sup> December 2019, being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Obligations") and which has been initialed by us for identification purposes.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Obligations") Listing Obligations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PKF Sridhar & Santhanam LLP

Chartered Accountants

Firm's Registration No. 003990S/S200018

S. Rajeshwari

Partner

Membership No. 024105

Place: Chennai Date: 28-01-2019

UDIN No: 20024105 AMARAD 3080